Researchers Propose Prakriti-Based Genomic Index to Predict Susceptibility to Inflammaging

A newly proposed mathematical model maps Ayurvedic constitutional phenotypes to cytokine single nucleotide polymorphisms to establish a Genetic Inflammatory Index that predicts susceptibility to inflammaging and epigenetic age acceleration.

In a study published in Frontiers in Immunology on July 29, 2026, researchers proposed a mathematical framework to predict an individual's susceptibility to inflammaging based on their unique constitutional phenotype, termed Prakriti.

The model introduces the Genetic Inflammatory Index (GII), which quantifies baseline genetic inflammatory tone using cytokine single nucleotide polymorphism (SNP) scores.

The authors hypothesized that Vata and Pitta dominant constitutions carry a pro-inflammatory genetic predisposition (GII > 0) and exhibit greater epigenetic age acceleration, whereas Kapha dominant constitutions possess an anti-inflammatory genetic resilience (GII < 0) and lower epigenetic age acceleration.

The paper outlines experimental designs to validate these hypotheses in age-stratified cohorts using principal-component-based (PC-based) epigenetic clocks, specifically PCGrimAge and PCPhenoAge.

Inflammaging—chronic, low-grade, systemic inflammation—is a recognized driver of age-related diseases, yet interindividual variation in its trajectory remains difficult to predict.

By correlating Ayurvedic phenotyping with modern 'ayurgenomics' (specifically cytokine SNP architecture and epigenetic aging rate), this model provides a structured, low-dimensional method to stratify baseline inflammatory tone.

The proposed framework offers a potential tool for predictive, preventive, personalized, and participatory (P4) medicine, aiding in clinical trial design and targeted public health strategies.

For the longevity and biotechnology sectors, the translation of qualitative phenotypic systems into quantitative, multi-variant biomarker panels (such as GII combined with epigenetic clocks) may refine how clinical trials stratify heterogeneous patient populations.

Therapeutic approaches targeting systemic immune-metabolic axes rather than isolated inflammatory pathways may gain clinical rationale from systems biology frameworks that map systemic, multi-organ homeostasis.

The initiation of prospective, Prakriti-stratified clinical trials utilizing validated assessment tools (such as CCRAS-PAS or ACPI) alongside PC-based epigenetic clocks to verify the predicted differences in biological age acceleration across constitutional groups.